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Ubiquitin ligases regulate numerous cellular processes, including tissue homeostasis, cellular
metabolism, and cell cycle progression. These enzymes recognize, interact with and ubiquitylate
specific substrates. Homologous to the E6-AP carboxyl terminus (HECT) and regulator of
chromosome condensation 1 (RCC1)-like domain-containing proteins (HERCs) belong to the
family of HECT ubiquitin ligases. There are six human HERCs which can be divided into two
subgroups: large HERCs (HERC1-2) and small HERCs (HERC3-6). Alterations in the function
of large HERCs are associated with serious pathologies such as neurological disorders. Mutations
in human HERC1 have been associated with overgrowth, intellectual disability and some autistic
features; while mutations in HERC2 have been identified as the cause of a neurodevelopmental
disorder with similarities to Angelman syndrome and autism (1).
Large HERCs are also known to be involved in human cancers. Mutations in HERC1 and
HERC2 have been detected in leukemia cells (T-cell acute lymphoblastic leukemia (T-ALL) for
HERC1 and T-cell prolymphocytic leukemia (T-PLL) for HERC1 and HERC2) and in breast cancer
tumors. Frameshift mutations in HERC2 have been reported in gastric and colorectal carcinomas
withmicrosatellite instability. HERC1 has been associated with non-melanoma skin cancer through
regulation of E6-mediated BAK degradation, and the HERC2 locus with cutaneous melanoma and
uveal melanoma (2–6).
More recent studies conducted by the Human Protein Atlas (7) confirm the involvement of
large HERCs in cancer (Figure 1A). Patients with kidney cancer, head and neck cancer, and
pancreatic cancer show greater survival when their HERC1 expression levels are higher (Figure 1A,
left). Similarly, greater survival is observed in renal cancer patients when HERC2 expression are
higher (Figure 1A, right). These expression data together with the observations described above
associating inactivating mutations of large HERCs with different types of cancer, suggest that these
genes exhibit a tumor suppressor function.
Despite all this evidence, the cellular functions of large HERCs in cancer are poorly understood.
Knowledge of these functions and the underlying molecular mechanisms should explain the role
as tumor suppressors that genetic analysis suggests large HERCs play. Up to now, the role of
large HERCs in cancer has mainly been attributed to the regulation of proteins involved in DNA
damage response such as MSH2, XPA, RNF8, or BRCA1 (1). Recent studies further propose
two novel molecular models for large HERCs that are compatible with their tumor suppressor
function (Figures 1B,C).
The first model emerges from the study performed by Schneider et al. (8). Those authors
demonstrate howHERC1 regulates ERK signaling. Classically, growth factors activate ERK through
activation of their receptors and the GEF/RAS/RAF/MEK signaling pathway (Figure 1B). Gain of
function of this pathway is associated with proliferation and tumorigenesis. Schneider et al. observe
that HERC1 knockdown induces cellular proliferation associated with an increase in ERK activity.
A specific rise in the amount of C-RAF accounts for this ERK activation. Pharmacological inhibitors
and RNA interference assays confirmed that regulation of ERK activity by HERC1 is dependent on
changes in C-RAF stability. HERC1 ubiquitylates C-RAF targeting it for proteasome-dependent
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FIGURE 1 | Large HERCs involved in cancer. (A) Gene expression of HERC1 and HERC2 in human cancers. Data were obtained from the Human Protein Atlas (7).
The Kaplan-Meier plots show the results from analysis of the correlation between patient survival and mRNA expression level for HERC1 (www.proteinatlas.org/
ENSG00000103657-HERC1/pathology) and HERC2 (www.proteinatlas.org/ENSG00000128731-HERC2/pathology). Patients were classified into one of two groups
based on the level of expression: low or high. (B,C) Molecular mechanisms of action of large HERCs as tumor suppressors: (B) HERC1 controls the ERK signaling
pathway, targeting C-RAF for proteasome-dependent degradation; (C) the HERC2-NEURL4 complex controls p53 transcriptional activity by regulating its
oligomerization state. See details in the text.
degradation. When levels of HERC1 are low, C-RAF degradation
decreases and its level is sufficient to activate the RAF/MEK/ERK
signaling pathway and cell proliferation (Figure 1B). This model
could account for the improved prognosis for cancer patients
when levels of HERC1 expression are higher (Figure 1A).
The second model emerges from studies performed by
Cubillos-Rojas et al. (9, 10). Those authors demonstrate how
HERC2 regulates p53 activity. p53 is a transcription factor
that regulates important cellular processes related to tumor
suppression, including induction of senescence, apoptosis, and
DNA damage response, as well as the inhibition of angiogenesis
and cell migration. p53 tetramerization is a key step in its
activation process and the regulation of this oligomerization
is an important control point. Cubillos-Rojas et al. show
that HERC2 interacts with the adaptor-like protein with six
neuralized domains (NEURL4) and that this complex controls
p53 transcriptional activity by regulation of its oligomerization
state (Figure 1C). Furthermore, the studies demonstrate that
regulation of p53 tetramerization by HERC2 is independent of
proteasome activity. The role of the HERC2-NEURL4 complex in
activating the tumor suppressor p53 could explain the improved
prognosis for cancer patients when levels of HERC2 expression
are higher (Figure 1A). According to this model, NEURL4
should also function as a tumor suppressor and in agreement with
this, analysis of cancer genomics datasets from the cBioPortal
shows a high frequency in NEURL4 deletions in prostate
cancer (10).
These two models for large HERCs are compatible
with a tumor suppressor function. This function is also
compatible with their role in the DNA damage response,
which could lead to a higher mutation burden (mutator
phenotype). All these findings highlight the important
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physiological role of large HERCs and how their loss of
function is associated with tumorigenesis. Knowing the
mechanisms through which large HERCs regulate cellular
processes may be helpful in identifying new prognostic
markers and in designing more specific and efficient
anti-cancer therapies.
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